Aura Biosciences, Inc.
$6.10-3.8%YTD+14.6%1Y-1.5%
Price updated 7h ago·X counts updated 5d ago
On X
The complete picture of $AURA on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.
457X posts · last 7 days
Chatter Meter
1.4×
How loud $AURA's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 94% of tracked names.
AI verdictAI analysisGenerated by AI from underlying data
TickerTalks' own read on what's driving $AURA — fundamentals, momentum, or an event — and whether it agrees with the X crowd.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $AURA.
Biotechnology
No material change from last week — mRNA oncology platform remains the structural driver.
What this means for $AURA
Neutral — Develops virus-like drug conjugate therapies targeting ocular melanoma and solid tumors; pre-commercial clinical-stage biotech.
Top industry ETF
$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-4.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-95.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-21.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-78.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 11, 2026$-0.48$-0.38-28.0%
Q1 2026May 11, 2026$-0.50$-0.40-25.0%
Q4 2025Mar 30, 2026$-0.37$-0.43+14.0%
Q3 2025Nov 13, 2025$-0.40$-0.46+13.0%
Next earningsThu, Nov 12·consensus EPS $-0.37
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.50$-30.0M
Q4 FY25$0———$-0.40$-20.6M
Q3 FY25$0———$-0.40$-20.2M
Q2 FY25$0———$-0.47$-20.8M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$19.2M$9.0M – $29.4M-$1.67-$1.77 – -$1.554
FY27$4.9M$2.3M – $7.5M-$1.52-$1.78 – -$1.263
FY28$34.1M$10.0M – $58.1M-$1.20-$1.24 – -$1.152
FY29$135.6M$63.5M – $207.7M-$0.58-$0.98 – -$0.181
FY30$221.0M$103.4M – $338.5M$0.03$0.01 – $0.051
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.28%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-12.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-8.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatMid float · 66.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.415-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
3New insider — initial holdingsAug 123
AI summary
3New insider — initial holdingsAug 123
AI summary
3New insider — initial holdingsAug 123
AI summary
S-3Shelf registrationAug 11S-3
AI summary
8-KRestructuring / exit costsAug 118-K — Item 2.02: Earnings release · Item 2.05: Restructuring / exit costs · Item 5.02: Officer or director change · Item 8.01: Other event
AI summary
8-KShareholder voteAug 58-K — Item 5.07: Shareholder vote
AI summary
3New insider — initial holdingsJul 83
AI summary
8-KOfficer or director changeJul 88-K — Item 5.02: Officer or director change
AI summary
+ 29 other (6 13Gs · 5 8-Ks · 4 proxys · 2 S-8s) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptAura Biosciences, Inc. $AURA Shares Bought by Frazier Life Sciences Management L.P.Aura Biosciences to Participate in Upcoming Investor ConferenceBlackRock Inc. Makes New Investment in Aura Biosciences, Inc. $AURAAura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 15 · last 7 days